About MyMD Pharmaceuticals®
As a clinical stage biopharma company, MyMD is developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. Our lead clinical candidate, MYMD-1® is an orally available, next-generation TNF-alpha inhibitor with the potential to transform the way TNF-alpha based diseases are treated.
With its small molecule design, selective mechanism of action, and ability to cross the blood brain barrier, MYMD-1® has the potential to disrupt the TNF-alpha inhibitor market and provide meaningful therapeutic solutions to patients not served by current therapies.
MYMD-1® has demonstrated the potential to slow the aging process and extend healthy lifespan. The product is being evaluated in Phase 2 studies for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications.
A second therapeutic candidate, Supera-CBD, is a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8,000 times more potent as a CB2 agonist (activator) than plant-based CBD. In addition to its potential role in managing anxiety, chronic pain and seizures, Supera-CBD has been shown to have anti-inflammatory effects.
